Goldman Sachs Group Inc. Has $25.14 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Goldman Sachs Group Inc. raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 3.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 824,527 shares of the company’s stock after acquiring an additional 28,264 shares during the period. Goldman Sachs Group Inc. owned approximately 0.86% of Intellia Therapeutics worth $25,140,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Opaleye Management Inc. bought a new stake in Intellia Therapeutics in the fourth quarter valued at about $3,019,000. Orchard Capital Management LLC boosted its stake in Intellia Therapeutics by 6.8% during the 4th quarter. Orchard Capital Management LLC now owns 170,006 shares of the company’s stock worth $5,183,000 after acquiring an additional 10,851 shares during the last quarter. Avidity Partners Management LP grew its holdings in Intellia Therapeutics by 18.0% during the fourth quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after purchasing an additional 68,334 shares during the period. Seven Eight Capital LP increased its stake in Intellia Therapeutics by 219.4% in the fourth quarter. Seven Eight Capital LP now owns 61,192 shares of the company’s stock valued at $1,866,000 after purchasing an additional 42,034 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in Intellia Therapeutics by 31.0% in the fourth quarter. Rafferty Asset Management LLC now owns 328,998 shares of the company’s stock worth $10,031,000 after purchasing an additional 77,873 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $25.00 on Tuesday. The business has a 50-day moving average of $23.63 and a 200-day moving average of $26.44. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -4.66 and a beta of 1.84. Intellia Therapeutics, Inc. has a fifty-two week low of $19.37 and a fifty-two week high of $46.50.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.29. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. The firm had revenue of $28.94 million during the quarter, compared to the consensus estimate of $15.60 million. On average, sell-side analysts expect that Intellia Therapeutics, Inc. will post -4.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Truist Financial reissued a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a report on Monday. BMO Capital Markets raised their price target on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Citigroup decreased their price objective on Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research report on Monday. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $69.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.